PE20110542A1 - Nuevos derivados de azabiclo[3.2.0]hept-3ilo, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados de azabiclo[3.2.0]hept-3ilo, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20110542A1
PE20110542A1 PE2010001083A PE2010001083A PE20110542A1 PE 20110542 A1 PE20110542 A1 PE 20110542A1 PE 2010001083 A PE2010001083 A PE 2010001083A PE 2010001083 A PE2010001083 A PE 2010001083A PE 20110542 A1 PE20110542 A1 PE 20110542A1
Authority
PE
Peru
Prior art keywords
hept
3ilo
azabiclo
propoxi
pharmaceutical compositions
Prior art date
Application number
PE2010001083A
Other languages
English (en)
Inventor
Patrick Casara
Alain Dhainaut
Fany Panayi
Anne-Marie Chollet
Pierre Lestage
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20110542A1 publication Critical patent/PE20110542A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO AZABICICLO DE FORMULA (I), DONDE ALK REPRESENTA UN GRUPO ALQUILENO C2-C4 Y W ES -NR'-CO-R O -CO-NR'-R; R' Y R SON H ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH U ALCOXI C1-C6. SON COMPUESTOS PREFERIDOS: 4-{3-[(1R,5S)-3-AZABICICLO[3.2.0]HEPT-3-IL]PROPOXI}BENZAMIDA, 4-{3-[(1R,5S)-3-AZABICICLO[3.2.0]HEPT-3-IL]PROPOXI}-N,N-DIMETILBENZAMIDA, N-(4-{3-[(1R,5S)-3-AZABICICLO[3.2.0]HEPT-3-IL]PROPOXI}FENIL)-N-METILACETAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE EL SISTEMA HISTAMINERGICO Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS COGNITIVOS ASOCIADOS CON EL ENVEJECIMIENTO CEREBRAL O CON ENFERMEDADES NEURODEGENERATIVAS, TRANSTORNOS DEL HUMOR, ENTRE OTROS
PE2010001083A 2009-12-09 2010-11-25 Nuevos derivados de azabiclo[3.2.0]hept-3ilo, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen PE20110542A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905957A FR2953514B1 (fr) 2009-12-09 2009-12-09 Nouveaux derives azabicyclo[3.2.0]hept-3-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20110542A1 true PE20110542A1 (es) 2011-08-18

Family

ID=42133738

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001083A PE20110542A1 (es) 2009-12-09 2010-11-25 Nuevos derivados de azabiclo[3.2.0]hept-3ilo, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen

Country Status (44)

Country Link
US (1) US8008337B2 (es)
EP (1) EP2332910B1 (es)
JP (1) JP5511645B2 (es)
KR (1) KR101292705B1 (es)
CN (1) CN102127004B (es)
AP (1) AP2755A (es)
AR (1) AR079268A1 (es)
AU (1) AU2010246426B2 (es)
BR (1) BRPI1005270A2 (es)
CA (1) CA2724151C (es)
CL (1) CL2010001309A1 (es)
CO (1) CO6280059A1 (es)
CR (1) CR11811A (es)
CU (1) CU23993B1 (es)
CY (1) CY1113971T1 (es)
DK (1) DK2332910T3 (es)
EA (1) EA018971B1 (es)
EC (1) ECSP10010649A (es)
ES (1) ES2405206T3 (es)
FR (1) FR2953514B1 (es)
GE (1) GEP20135801B (es)
HN (1) HN2010002593A (es)
HR (1) HRP20130307T1 (es)
IL (1) IL209463A (es)
JO (1) JO2880B1 (es)
MA (1) MA32444B1 (es)
ME (1) ME01504B (es)
MX (1) MX2010013093A (es)
MY (1) MY150598A (es)
NI (1) NI201000206A (es)
NZ (1) NZ589763A (es)
PE (1) PE20110542A1 (es)
PL (1) PL2332910T3 (es)
PT (1) PT2332910E (es)
RS (1) RS52698B (es)
SA (1) SA110320007B1 (es)
SG (1) SG172543A1 (es)
SI (1) SI2332910T1 (es)
SV (1) SV2010003746A (es)
TW (1) TWI419875B (es)
UA (1) UA106721C2 (es)
UY (1) UY33046A (es)
WO (1) WO2011070250A1 (es)
ZA (1) ZA201008651B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9300625B (sl) * 1993-12-02 2002-02-28 Basf Aktiengesellschaft N-substituirani derivati azabicikloheptana, njihova priprava in uporaba
DE4341402A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SV2010003746A (es) 2011-03-15
IL209463A (en) 2014-06-30
AR079268A1 (es) 2012-01-04
HRP20130307T1 (hr) 2013-04-30
ME01504B (me) 2014-04-20
EP2332910A1 (fr) 2011-06-15
MX2010013093A (es) 2011-06-14
SI2332910T1 (sl) 2013-05-31
CA2724151A1 (fr) 2011-06-09
CR11811A (es) 2011-02-04
AP2755A (en) 2013-09-30
EA018971B1 (ru) 2013-12-30
CU20100236A7 (es) 2011-11-15
JO2880B1 (en) 2015-03-15
MA32444B1 (fr) 2011-07-03
JP5511645B2 (ja) 2014-06-04
KR20110065384A (ko) 2011-06-15
US8008337B2 (en) 2011-08-30
UA106721C2 (uk) 2014-10-10
ZA201008651B (en) 2011-10-26
FR2953514B1 (fr) 2011-12-23
NZ589763A (en) 2012-05-25
TW201200498A (en) 2012-01-01
NI201000206A (es) 2014-01-07
CN102127004B (zh) 2013-10-23
US20110136886A1 (en) 2011-06-09
ES2405206T3 (es) 2013-05-30
EA201001755A1 (ru) 2011-10-31
GEP20135801B (en) 2013-04-10
PT2332910E (pt) 2013-02-26
CA2724151C (fr) 2013-03-26
AP2010005489A0 (en) 2010-12-31
BRPI1005270A2 (pt) 2013-04-30
MY150598A (en) 2014-01-30
HN2010002593A (es) 2013-03-18
ECSP10010649A (es) 2011-07-29
AU2010246426B2 (en) 2013-06-27
CL2010001309A1 (es) 2012-01-13
RS52698B (en) 2013-08-30
CO6280059A1 (es) 2011-05-20
JP2011121945A (ja) 2011-06-23
CY1113971T1 (el) 2016-07-27
PL2332910T3 (pl) 2013-06-28
FR2953514A1 (fr) 2011-06-10
CN102127004A (zh) 2011-07-20
AU2010246426A1 (en) 2011-06-23
CU23993B1 (es) 2014-04-24
EP2332910B1 (fr) 2013-01-30
DK2332910T3 (da) 2013-05-13
IL209463A0 (en) 2011-02-28
SG172543A1 (en) 2011-07-28
WO2011070250A1 (fr) 2011-06-16
SA110320007B1 (ar) 2013-10-03
UY33046A (es) 2011-05-31
KR101292705B1 (ko) 2013-08-02
TWI419875B (zh) 2013-12-21

Similar Documents

Publication Publication Date Title
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
CL2018000666A1 (es) Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
UY35288A (es) Piridonamidas como moduladores de canales de sodio
AR076460A1 (es) Antagonistas del receptor cxcr3
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
BR112013017316A2 (pt) compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
AR085471A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
AR075050A1 (es) Dicianopiridinas alquilamino-sustituidas
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
AR067927A1 (es) Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
CU20150058A7 (es) Derivados de imidazopiridazina como receptores de moduladores gabaa
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
MX2021004134A (es) Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed